{
    "nctId": "NCT02314156",
    "briefTitle": "Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy",
    "officialTitle": "Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy",
    "overallStatus": "COMPLETED",
    "conditions": "BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma In Situ, Lobular Breast Carcinoma In Situ, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 67,
    "primaryOutcomeMeasure": "Mean Levels of Telapristone Acetate in Breast Tissue",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women scheduled for unilateral or bilateral mastectomy for breast cancer therapy, pathology confirmed stage 0-II (including ductal carcinoma in situ), or prophylaxis (breast cancer, early onset \\[BRCA\\] mutation carriers, women with strong family history or lobular carcinoma in situ or other conditions where prophylactic mastectomy has been elected)\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\< 1 (Karnofsky \\>= 70%)\n* Total bilirubin \\< 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) \\< 2.5 x ULN\n* Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) \\< 2.5 x ULN\n* Creatinine \\< 2 x ULN\n* Alkaline phosphatase \\< 2.5 x ULN\n* Blood urea nitrogen \\< 2 x ULN\n* Willing to use non-hormonal contraception (adequate barrier-type contraception or intrauterine device \\[IUD\\]) from the time the pregnancy test is performed for the duration of study participation, and 30 days after study drug cessation (for women of childbearing potential only)\n* Ability to understand and the willingness to sign a written informed consent document\n* Willing and able to schedule mastectomy 4 weeks (+/- 7days) following start of study agent\n* Willing to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of study agent dosing\n* Negative urine pregnancy test result, for participants of child bearing potential, within 5 days prior to first dose of study medication; female of child-bearing potential is any woman (regardless of sexual orientation, whether she has undergone a tubal ligation, or remains celibate by choice) who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; OR has had a menstrual period at any time in the preceding 12 consecutive months)\n* Willing to use alcohol in moderation while taking study agent\n\nExclusion Criteria:\n\n* The presence of skin invasion by the breast cancer, or inflammatory changes with skin edema AND erythema. Note: Paget's disease is permitted.\n* Women receiving a \"nipple delay\" procedure prior to mastectomy.\n* Women with skin diseases (psoriasis, eczema) on breast.\n* A history of thromboembolic disorder or cerebral vascular disease\n* Use of oral contraceptives or other hormonal treatments within eight weeks prior to the randomization or during the period of the study; women should not have used Depo-Provera in the preceding 6 months; use of hormone coated IUD like Mirena is allowed\n* Participants may not have received any other investigational agents in the previous 3 months\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to telapristone (i.e. other progesterone antagonists)\n* Taken tamoxifen or other selective estrogen/progesterone receptor modulators (SERMs/SPRMs) within two years prior to entering study or been required to discontinue SERM therapy due to thromboembolic or uterine toxicity\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* History of prior breast cancer-specific therapy within the previous 2 years; previous unilateral radiation in women scheduled for mastectomy of the contralateral side is allowed\n* Pregnant or breastfeeding\n* Currently taking spironolactone\n* Recent history (within 6 months) of alcoholism or drug abuse\n* Known active infection with human immunodeficiency virus (HIV), hepatitis A, B, or C",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}